More than 600,000 people in the United States are living with a primary brain tumor — one that begins and stays in the brain — and over 60,000 adults and children will be diagnosed with a brain tumor this year.
In recognition of May as Brain Tumor Awareness Month, we asked David Reardon, MD, clinical director of the Center for Neuro-Oncology at Dana-Farber/Brigham and Women’s Cancer Center, for the latest advances in brain tumor research and patient care.
By James Bond “How long will I live?” I asked my oncologist in Ohio in 1992, when I was 44 and diagnosed with multiple myeloma. “Three years,” he answered. Instead, I enjoyed 10 more years of active living. Then my disease began to overtake me; my kidneys were failing, I was unable to eat solid … Read more
When it comes to finding better drugs for cancer, Dana-Farber oncologist Dr. David Frank is not a patient man. While new cancer science promises to bring novel, improved therapies to the bedside, it can take many years — and Frank isn’t willing to wait.
“We need to get new treatments to patients as soon as possible,” he says.
Activated by sunlight and present in some foods and supplements, vitamin D has been associated with healthy bones and reducing the risk of diabetes and cancer. But a new study says that the recommended dose of vitamin D needed to reap these health benefits remains unclear. To help shed some light on the topic, we … Read more
At this year’s American Society of Hematology Annual Meeting, Dana-Farber scientists presented major findings that could one day improve diagnosis and treatment of blood cancers, extend life, or even cure some diseases. Among the highlights: Steven Treon, MD, PhD, and his colleagues identified a gene mutation that underlies the vast majority of cases of Waldenström’s … Read more